vs
Apellis Pharmaceuticals, Inc.（APLS）与世纪互联（VNET）财务数据对比。点击上方公司名可切换其他公司
世纪互联的季度营收约是Apellis Pharmaceuticals, Inc.的1.8倍（$362.7M vs $199.9M），世纪互联净利率更高（-10.7% vs -29.5%，领先18.8%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-193.1M），过去两年世纪互联的营收复合增速更高（17.4% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
VNET Group即世纪互联，是中国领先的第三方中立数据中心服务商，提供机柜托管、云基础设施、混合云部署及网络管理等解决方案，服务覆盖科技、金融、零售等多领域企业客户，为企业数字化运营提供稳定的算力与网络支撑。
APLS vs VNET — 直观对比
营收规模更大
VNET
是对方的1.8倍
$199.9M
净利率更高
VNET
高出18.8%
-29.5%
自由现金流更多
APLS
多$178.8M
$-193.1M
两年增速更快
VNET
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $362.7M |
| 净利润 | $-59.0M | $-38.7M |
| 毛利率 | — | 20.9% |
| 营业利润率 | -25.6% | 0.5% |
| 净利率 | -29.5% | -10.7% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSVNET
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $362.7M | ||
| Q2 25 | $178.5M | — | ||
| Q1 25 | $166.8M | $309.5M | ||
| Q4 24 | $212.5M | — | ||
| Q3 24 | $196.8M | $302.2M | ||
| Q2 24 | $199.7M | $274.4M | ||
| Q1 24 | $172.3M | $262.9M |
净利润APLSVNET
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-38.7M | ||
| Q2 25 | $-42.2M | — | ||
| Q1 25 | $-92.2M | $-2.4M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $-2.1M | ||
| Q2 24 | $-37.7M | $-1.1M | ||
| Q1 24 | $-66.4M | $-22.0M |
毛利率APLSVNET
| Q4 25 | — | — | ||
| Q3 25 | — | 20.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 25.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | — | 21.3% | ||
| Q1 24 | — | 21.6% |
营业利润率APLSVNET
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 0.5% | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | 0.1% | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | 24.5% | ||
| Q2 24 | -14.7% | 0.2% | ||
| Q1 24 | -36.0% | 0.2% |
净利率APLSVNET
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -10.7% | ||
| Q2 25 | -23.6% | — | ||
| Q1 25 | -55.3% | -0.8% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | -0.7% | ||
| Q2 24 | -18.9% | -0.4% | ||
| Q1 24 | -38.5% | -8.4% |
每股收益（稀释后）APLSVNET
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $492.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $890.8M |
| 总资产 | $1.1B | $6.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSVNET
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $492.1M | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | $544.3M | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | $219.5M | ||
| Q2 24 | $360.1M | $247.2M | ||
| Q1 24 | $325.9M | $246.9M |
总债务APLSVNET
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSVNET
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $890.8M | ||
| Q2 25 | $156.3M | — | ||
| Q1 25 | $164.2M | $927.8M | ||
| Q4 24 | $228.5M | — | ||
| Q3 24 | $237.1M | $902.9M | ||
| Q2 24 | $264.3M | $900.6M | ||
| Q1 24 | $266.7M | $895.1M |
总资产APLSVNET
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $6.1B | ||
| Q2 25 | $821.4M | — | ||
| Q1 25 | $807.3M | $5.4B | ||
| Q4 24 | $885.1M | — | ||
| Q3 24 | $901.9M | $4.3B | ||
| Q2 24 | $904.5M | $4.0B | ||
| Q1 24 | $831.9M | $3.9B |
负债/权益比APLSVNET
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $113.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-193.1M |
| 自由现金流率自由现金流/营收 | -7.1% | -53.2% |
| 资本支出强度资本支出/营收 | 0.1% | 84.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-589.7M |
8季度趋势，按日历期对齐
经营现金流APLSVNET
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $113.8M | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | $27.0M | ||
| Q4 24 | $19.4M | — | ||
| Q3 24 | $34.1M | $108.3M | ||
| Q2 24 | $-8.3M | $55.8M | ||
| Q1 24 | $-133.0M | $37.1M |
自由现金流APLSVNET
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $-193.1M | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | $-220.0M | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | $-95.0M | ||
| Q2 24 | $-8.4M | $-81.6M | ||
| Q1 24 | $-133.3M | $-102.2M |
自由现金流率APLSVNET
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | -53.2% | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | -71.1% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | -31.4% | ||
| Q2 24 | -4.2% | -29.8% | ||
| Q1 24 | -77.3% | -38.9% |
资本支出强度APLSVNET
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 84.6% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | 79.8% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 67.3% | ||
| Q2 24 | 0.0% | 50.1% | ||
| Q1 24 | 0.2% | 53.0% |
现金转化率APLSVNET
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
VNET
暂无分部数据
